152 Results for "

CYP2C9

" in MedChemExpress (MCE) Product Catalog:
Products (152)

152 Results for "CYP2C9" in MCE Product Catalog:

Cat. No.: HY-Z2667
CAS No.: 119141-89-8
Synonyms: (R)-Omeprazole; (+)-Omeprazole
(R)-Esomeprazole ((R)-Omeprazole; (+)-Omeprazole) is an orally active cytochrome P450 2C19, CYP3A4, and CYP2C9-related metabolic modulator. (R)-Esomeprazole can be used in studies of digestive system diseases and compound metabolic interactions .
loading...
    loading...
Cat. No.: HY-177070
CAS No.: 2640653-91-2
Target:  

Xanthine Oxidase

Research Areas:  

Inflammation/Immunology

Angexostat (Compound 2) is an inhibitor of xanthine oxidase. Angexostat exhibits high permeability. Angexostat inhibits CYP2C9 with an IC50 of 18.1 μM. Angexostat can be studied in research for xanthine oxidase-related diseases such as hyperuricemia and gout .
loading...
    loading...
Cat. No.: HY-W140208
CAS No.: 2404-87-7
Target:  

Cytochrome P450

Research Areas:  

Neurological Disease

3-Phenylthiophene (Compound 25) is a CYP2A6 inhibitor with a Ki value of 3.3 μM. The Ki values for CYP2E1, CYP2B6, CYP2C9, and CYP2C19 are 9.7, 14, 112, and 107 μM respectively. It shows no significant inhibition on CYP3A4 and CYP2D6. 3-Phenylthiophene can be used in smoking cessation research .
loading...
    loading...
Cat. No.: HY-135111
CAS No.: 110374-16-8
4-Desmethoxy Omeprazole is a metabolite of Omeprazole (HY-B0113) and an impurity in its preparation process. Omeprazole is an orally active H+,K+-ATPase inhibitor and also a proton pump inhibitor. Omeprazole competitively inhibits the activity of CYP2C19, CYP3A4, and CYP2C9. Omeprazole inhibits gastric acid secretion and can be used for the treatment of acid-related gastrointestinal disorders. Omeprazole also has neuroprotective and antibacterial effects .
loading...
    loading...
Cat. No.: HY-17356G
CAS No.: 49562-28-9
Fenofibrate (GMP) is Fenofibrate (HY-17356) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.
loading...
    loading...
Cat. No.: HY-12946A
CAS No.: 1198784-97-2
BI 653048 phosphate is a selective and orally active nonsteroidal glucocorticoid (GC) agonist with an IC50 value of 55 nM . BI 653048 phosphate inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms’ activity and reduces affinity for the hERG ion channel (IC50>30 μM) . BI 653048 phosphate is extracted from patent WO2005028501A1 (Compound 103), is also a HCV NS3 protease inhibitor that can reduce viral loads infected with the hepatitis C virus .
loading...
    loading...
Cat. No.: HY-164031
CAS No.: 4052-13-5
Target:  

Cytochrome P450

Research Areas:  

Neurological Disease

Cloperidone acts as an inhibitor and substrate of CYP2C9, with an IC50 of 17.7 μM. Cloperidone exhibits enhanced cytotoxicity in cells expressing CYP2C9. It can be used in the research of sedative/hypnotic-related diseases .
loading...
    loading...
Cat. No.: HY-167872
CAS No.: 108210-73-7
Target:  

Cytochrome P450

Research Areas:  

Others

Bifeprofen, a cytochrome P450 2C9 (CYP2C9) inhibitor, exhibits dose-dependent inhibition (75 μM, 50%) .
loading...
    loading...
Cat. No.: HY-N0893S
CAS No.: 1794898-13-7
Synonyms: HZIV 81-2 d6
Tetrahydrocurcumin-d6 is a deuterium labeled Tetrahydrocurcumin. Tetrahydrocurcumin is a Curcuminoid which displays inhibitory activity for CYP2C9 and CYP3A4 .
loading...
    loading...
Cat. No.: HY-145490
CAS No.: 600177-94-4
Target:  

Drug Metabolite

Research Areas:  

Metabolic Disease

trans-hydroxy Glimepiride is an active metabolite of the sulfonylurea Glimepiride (HY-B0104). It is formed from glimepiride primarily in the liver by the cytochrome P450 (CYP) isoform CYP2C9.
loading...
    loading...
Cat. No.: HY-116601
CAS No.: 17834-02-5
Target:  

Cytochrome P450

Research Areas:  

Others

6-Hydroxywarfarin is a metabolite of (+) -warfarin. 6-Hydroxywarfarin is a weaker vitamin K antagonist. 6-Hydroxywarfarin is metabolized by the cytochrome P450 isomer 2C9 (CYP2C9) .
loading...
    loading...
Cat. No.: HY-134999
CAS No.: 83219-99-2
Research Areas:  

Metabolic Disease

10-Hydroxywarfarin, a metabolite of (R)-(+)-Warfarin (HY-W015998 ), is a CYP2C9 and vitamin K epoxide reductase complex 1 (VKOR) inhibitor with IC50s of 1.6 µM and 80 ng/mL, respectively .
loading...
    loading...
Cat. No.: HY-119996
CAS No.: 873327-59-4
AR-C141990 (Compound 30) is a potent blocker of the monocarboxylate transporter MCT1 with a Ki of 4.8 nM. AR-C141990 (Compound 30) inhibits CYP3A4 and CYP2C9 with IC50 values of 16 μM .
loading...
    loading...
Cat. No.: HY-151253
CAS No.: 3010895-54-9
Research Areas:  

Infection

CYP2C1/CYP2C19-IN-2 (compound 21d) is a potent CYP2C9/CYP2C19 inhibitor, possessing no hepatotoxicity and ames toxicity. CYP2C1/CYP2C19-IN-2 can be used in study of anti-ZIKV .
loading...
    loading...
Cat. No.: HY-153970
CAS No.: 1632002-28-8
Target:  

URAT1

Research Areas:  

Inflammation/Immunology

URAT1 inhibitor 7 (compound 10f) is a potent URAT1 inhibitor, with an IC50 of 12 nM. URAT1 inhibitor 7 exhibits microsomal stability (HLM <13 µL/min/mg). URAT1 inhibitor 7 also inhibits CYP2C9, with an IC50 of 4.2 μM. URAT1 inhibitor 7 can be used for gout research .
loading...
    loading...
Cat. No.: HY-15550S1
CAS No.: 1189656-64-1
4'-Hydroxy diclofenac- 13C6 is the 13C labeled 4'-Hydroxy diclofenac . 4'-Hydroxy diclofenac is an orally active metabolite of Diclofenac (HY-15036) by cytochrome P450 2C9 (CYP2C9). 4'-Hydroxy diclofenac has anti-inflammatory and analgesic properties .
loading...
    loading...
Cat. No.: HY-135390
CAS No.: 253688-62-9
Synonyms: Ro 64-1056
Target:  

Drug Metabolite

Research Areas:  

Cardiovascular Disease

Hydroxy desmethyl Bosentan (Ro 64-105) is a Bosentan metabolism produced by the cytochrome P450 enzymes CYP2C9 and CYP3A4 in the liver . Bosentan is a competitive and dual antagonist of endothelin-1 (ET) for the ETA and ETB receptors with Ki of 4.7 nM and 95 nM in human SMC, respectively. Bosentan can be used in treatment of pulmonary arterial hypertension .
loading...
    loading...
Cat. No.: HY-179154
Research Areas:  

Metabolic Disease

α-Glucosidase-IN-101 (Compound 13j) is an uncompetitive α-glucosidase inhibitor, with an IC50 of 120 nM. α-Glucosidase-IN-101 properly inhibits CYP1A2, CYP2C19, and CYP2C9 isoforms of cytochrome P450. α-Glucosidase-IN-101 can be used in the research of diabetes .
loading...
    loading...
Cat. No.: HY-175169
Target:  

Bacterial Urease

Research Areas:  

Infection

Urease-IN-21 (Compound 11b) is a Urease inhibitor with an IC50 of 0.12  μM. Urease-IN-21 has potent antibacterial activity against helicobacter pylori (H. pylori) and inhibitor activity against P450 enzyme (CYP2C19, CYP2C9, and CYP3A4). Urease-IN-21 can be used for H. pylori infection research .
loading...
    loading...
Cat. No.: HY-143906
CAS No.: 2803951-18-8
Target:  

URAT1

Research Areas:  

Inflammation/Immunology

URAT1 inhibitor 2 is an orally active and potent URAT1 and CYP isozyme inhibitor, with IC50 values of 1.36 μM, 16.97 μM, 5.22 μM for URAT1-mediated 14C-UA uptake, CYP1A2 and CYP2C9, respectively. URAT1 inhibitor 2 is a promising agent candidate in the study of hyperuricemia and gout .
loading...
    loading...